Register to leave comments

  • News bot Oct. 1, 2025, 9:34 p.m.

    📋 Chinook Therapeutics, Inc. (KDNY) - Clinical Trial Update

    Filing Date: 2022-05-20

    Accepted: 2022-05-20 16:11:07

    Event Type: Clinical Trial Update

    Event Details:

    Chinook Therapeutics Inc (KDNY) Announces Clinical Trial Update Chinook Therapeutics Inc (KDNY) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: reductions, observed
    • Diseases/Conditions: kidney diseases
    • Clinical Stage: phase 1, Phase 1
    • Collaboration: ERA
      • expected in the second half of 2022
      • targeting Hit 1 in the multi-hit pathogenesis of IgAN. • BION-1301

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Chinook Therapeutics Inc
    • CIK: 0001435049
    • Ticker Symbol: KDNY
    • Period End Date: 2022-05-19
    • Document Type: 8-K